Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

PMID:
29685880
2.

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.

Komdeur FL, Wouters MC, Workel HH, Tijans AM, Terwindt AL, Brunekreeft KL, Plat A, Klip HG, Eggink FA, Leffers N, Helfrich W, Samplonius DF, Bremer E, Wisman GB, Daemen T, Duiker EW, Hollema H, Nijman HW, de Bruyn M.

Oncotarget. 2016 Nov 15;7(46):75130-75144. doi: 10.18632/oncotarget.12077.

3.

CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.

Workel HH, Komdeur FL, Wouters MC, Plat A, Klip HG, Eggink FA, Wisman GB, Arts HJ, Oonk MH, Mourits MJ, Yigit R, Versluis M, Duiker EW, Hollema H, de Bruyn M, Nijman HW.

Eur J Cancer. 2016 Jun;60:1-11. doi: 10.1016/j.ejca.2016.02.026. Epub 2016 Mar 31.

PMID:
27038842
4.

Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods.

Alkema NG, Tomar T, Duiker EW, Jan Meersma G, Klip H, van der Zee AG, Wisman GB, de Jong S.

Sci Rep. 2015 Oct 6;5:14495. doi: 10.1038/srep14495.

5.

Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.

Wouters MC, Komdeur FL, Workel HH, Klip HG, Plat A, Kooi NM, Wisman GB, Mourits MJ, Arts HJ, Oonk MH, Yigit R, de Jong S, Melief CJ, Hollema H, Duiker EW, Daemen T, de Bruyn M, Nijman HW.

Clin Cancer Res. 2016 Feb 1;22(3):714-24. doi: 10.1158/1078-0432.CCR-15-1617. Epub 2015 Sep 18.

6.

A novel phenotype of a hepatocyte nuclear factor homeobox A (HNF1A) gene mutation, presenting with neonatal cholestasis.

de Vries AG, Bakker-van Waarde WM, Dassel AC, Losekoot M, Duiker EW, Gouw AS, Bodewes FA.

J Hepatol. 2015 Nov;63(5):1295-7. doi: 10.1016/j.jhep.2015.08.005. Epub 2015 Aug 22. No abstract available.

PMID:
26307397
7.

Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.

Duiker EW, Dijkers EC, Lambers Heerspink H, de Jong S, van der Zee AG, Jager PL, Kosterink JG, de Vries EG, Lub-de Hooge MN.

Br J Pharmacol. 2012 Apr;165(7):2203-12. doi: 10.1111/j.1476-5381.2011.01718.x.

8.

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.

Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S.

Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.

9.

The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.

Duiker EW, van der Zee AG, de Graeff P, Boersma-van Ek W, Hollema H, de Bock GH, de Jong S, de Vries EG.

Gynecol Oncol. 2010 Mar;116(3):549-55. doi: 10.1016/j.ygyno.2009.09.014. Epub 2009 Dec 3.

PMID:
19959214
10.

Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.

Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S.

Clin Cancer Res. 2009 Mar 15;15(6):2048-57. doi: 10.1158/1078-0432.CCR-08-1535. Epub 2009 Mar 10.

11.

The clinical trail of TRAIL.

Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, de Vries EG.

Eur J Cancer. 2006 Sep;42(14):2233-40. Epub 2006 Aug 1. Review.

PMID:
16884904
12.

Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy.

Crijns AP, Duiker EW, de Jong S, Willemse PH, van der Zee AG, de Vries EG.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:152-65. Review.

PMID:
16515584

Supplemental Content

Loading ...
Support Center